相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway
Maria De Grandis et al.
BLOOD (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis
Rakhee Vaidya et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients
Veronika Buxhofer-Ausch et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis
Tiziano Barbui et al.
BLOOD (2012)
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
Jasper H. Smalberg et al.
BLOOD (2012)
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort
Peter J. Campbell et al.
BLOOD (2012)
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
Silvia Pascale et al.
BLOOD (2012)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Tiziano Barbui et al.
BLOOD (2012)
Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome
Fiorina Giona et al.
BLOOD (2012)
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years
Francesca Palandri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pregnancy in women with portal vein thrombosis: Results of a multicentric European study on maternal and fetal management and outcome
J. Hoekstra et al.
JOURNAL OF HEPATOLOGY (2012)
Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders
Tanima De et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2012)
Neutrophil extracellular traps promote deep vein thrombosis in mice
A. Brill et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
The JAK2 V617F mutation in patients with cerebral venous thrombosis
S. M. Passamonti et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis
Ipek Yonal et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2012)
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
G. Finazzi et al.
LEUKEMIA (2012)
How to manage children and young adults with myeloproliferative neoplasms
T. Barbui
LEUKEMIA (2012)
Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia
Norma Maugeri et al.
BLOOD (2011)
JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients
Marina Panova-Noeva et al.
BLOOD (2011)
Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4
Fabrizio Semeraro et al.
BLOOD (2011)
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification
Juergen Thiele et al.
BLOOD (2011)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
Francesco Passamonti et al.
BLOOD (2011)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
Alessandra Carobbio et al.
BLOOD (2011)
Polymorphonuclear neutrophils from JAK2v617F positive MPD patients do not support hypercoagulability: A study with calibrated automated thrombography (CAT)
Julien Perrin et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera
Khadija Abdulkarim et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
Tiziano Barbui et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Myeloproliferative Disorders in Pregnancy
Claire N. Harrison et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
Jean-Jacques Kiladjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms
J. Hoekstra et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Aspirin in low-risk essential thrombocythemia, not so simple after all?
Claire Harrison et al.
LEUKEMIA RESEARCH (2011)
The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis
D. W. Orr et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
JAK2 Mutations Across a Spectrum of Venous Thrombosis Cases
Shrimati Shetty et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
Valerio De Stefano et al.
ANNALS OF HEMATOLOGY (2010)
Thrombosis in primary myelofibrosis: incidence and risk factors
Tiziano Barbui et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Monocyte IL-2Rα expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms
N. P. Goette et al.
CYTOKINE (2010)
Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
Michelle Ann Elliott et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Acute Portal Vein Thrombosis Unrelated to Cirrhosis: A Prospective Multicenter Follow-up Study
Aurelie Plessier et al.
HEPATOLOGY (2010)
Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients
F. Girodon et al.
LEUKEMIA (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms
Giuseppe Cella et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy
Francesca Palandri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Etiology, Management, and Outcome of the Budd-Chiari Syndrome
Sarwa Darwish Murad et al.
ANNALS OF INTERNAL MEDICINE (2009)
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
Selcuk Sozer et al.
BLOOD (2009)
JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
Alessandra Carobbio et al.
EXPERIMENTAL HEMATOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
JAK2-V617F mutation in cerebral venous thrombosis
K. Koopman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
Federico Lussana et al.
THROMBOSIS RESEARCH (2009)
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera
Marina Marchetti et al.
BLOOD (2008)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2008)
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia:: a retrospective survey
Marco Ruggeri et al.
BLOOD (2008)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients
Francesca Santilli et al.
BLOOD (2008)
Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis
Sandra Guerra Xavier et al.
BLOOD COAGULATION & FIBRINOLYSIS (2008)
JAK2V617F mutation in patients with portal vein thrombosis
Yusuf Bayraktar et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
Prevention of thrombosis in polycythemia vera and essential thrombocythemia
Raffaele Landolfi et al.
HAEMATOLOGICA (2008)
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Francesco Passamonti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation
R. Landolfi et al.
LEUKEMIA (2008)
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
F. Cervantes et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Beneficial suicide: why neutrophils die to make NETs
Volker Brinkmann et al.
NATURE REVIEWS MICROBIOLOGY (2007)
Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin α5 chain and Lu/BCAM
Marie-Paule Wautier et al.
BLOOD (2007)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
Essential thrombocythemia in young individuals:: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients
A. Alvarez-Larran et al.
LEUKEMIA (2007)
The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia
Ayalew Tefferi et al.
BLOOD (2007)
JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses
Christine McMahon et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders
V. De Stefano et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
Alessandra Carobbio et al.
BLOOD (2007)
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
D. Colaizzo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis
S. Regina et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The haematocrit and platelet target in polycythemia vera
Marcello Di Nisio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
Guido Finazzi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis
Massimo Primignani et al.
HEPATOLOGY (2006)
Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?
Ayalew Tefferi et al.
BLOOD (2006)
Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications
Naseema Gangat et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome
Raj K. Patel et al.
GASTROENTEROLOGY (2006)
Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia
Naseema Gangat et al.
CANCER (2006)
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
AP Wolanskyj et al.
MAYO CLINIC PROCEEDINGS (2006)
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
A Tefferi et al.
CANCER (2006)
Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution
F Cervantes et al.
LEUKEMIA (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
E Antonioli et al.
LEUKEMIA (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pregnancy and its management in the Philadelphia negative myeloproliferative diseases
C Harrison
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients
T Bachleitner-Hofmann et al.
THROMBOSIS RESEARCH (2003)
Factor V Leiden mutation carriership and venous thromboembolism in Polycythemia Vera and Essential Thrombocythemia
M Ruggeri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia
R Jantunen et al.
ANNALS OF HEMATOLOGY (2001)
Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area
MK Jensen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
MK Jensen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Essential thrombocythemia in young adults: Major thrombotic complications and complications during pregnancy - A follow-up study in 68 patients
ML Randi et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2000)
分享论文
